{"id":482229,"date":"2024-01-11T08:57:38","date_gmt":"2024-01-11T13:57:38","guid":{"rendered":"https:\/\/platohealth.ai\/dr-paloma-h-giangrande-appointed-cto-at-eleven-therapeutics-a-prominent-figure-in-nucleic-acid-therapeutics-for-over-a-decade-medical-device-news-magazine\/"},"modified":"2024-01-11T09:02:55","modified_gmt":"2024-01-11T14:02:55","slug":"dr-paloma-h-giangrande-appointed-cto-at-eleven-therapeutics-a-prominent-figure-in-nucleic-acid-therapeutics-for-over-a-decade-medical-device-news-magazine","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/dr-paloma-h-giangrande-appointed-cto-at-eleven-therapeutics-a-prominent-figure-in-nucleic-acid-therapeutics-for-over-a-decade-medical-device-news-magazine\/","title":{"rendered":"Dr Paloma H Giangrande Appointed CTO At Eleven Therapeutics | A Prominent Figure In Nucleic Acid Therapeutics For Over A Decade – Medical Device News Magazine","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
<\/div>\n
\n

Dr Paloma H Giangrande<\/p>\n

Eleven Therapeutics, a pioneering biotechnology company specializing in next-generation mRNA therapeutics, proudly announces the appointment of Dr Paloma H Giangrande as the company\u2019s Chief Technology Officer (CTO). Dr. Giangrande, an esteemed leader in the field of nucleic acid therapeutics, will play a pivotal role in advancing the company\u2019s core xRNA technologies and platforms.<\/h4>\n

Bringing a wealth of experience, Dr. Giangrande has been a prominent figure in nucleic acid therapeutics for over a decade. Her groundbreaking work at the University of Iowa involved pioneering multiple nucleic acid technologies. Subsequently, she held key leadership roles at renowned biotechnology companies, including as Director of Rare Diseases at Moderna, where she spearheaded mRNA therapeutic programs for rare genetic diseases. Her most recent position was as VP of Platform and Discovery at Wave Life Sciences, leading the groundbreaking RNA Editing program to a first-in-human stage. Dr. Giangrande currently holds the prestigious role of Editor-in-Chief at Molecular Therapy Nucleic Acids, the field\u2019s foremost scientific journal.<\/p>\n

In her new capacity as CTO at Eleven Therapeutics, Dr. Giangrande will drive the strategic direction for the company\u2019s core xRNA technologies and platforms. Her expertise will be instrumental in integrating these cutting-edge technologies into therapeutic applications, solidifying Eleven Therapeutics\u2019 position as a leader in nucleic acid therapeutics.<\/p>\n

\u201cWe are thrilled to welcome Dr. Paloma Giangrande to Eleven Therapeutics. Her expertise specifically in our company\u2019s field of specialization and her remarkable leadership track record will significantly bolster our capabilities in advancing innovation. Dr. Giangrande\u2019s appointment represents a strategic milestone as we continue to revolutionize mRNA therapeutics and pave the way for transformative new horizons in the treatment of diseases with unmet needs.\u201d<\/p>\n

Dr Paloma H Giangrande Replied<\/h2>\n

\u201cJoining Eleven Therapeutics is an exciting opportunity for me to apply my expertise to crucial biotechnological challenges,\u201d said Dr. Giangrande. \u201cI\u2019m enthusiastic about contributing to the groundbreaking research conducted here. Along Eleven\u2019s strong team and innovative approach, I look forward to leveraging my strategic insights and experience to accelerate the development of cutting-edge nucleic acid therapeutics, and beyond.\u201d<\/p>\n

Conclusion<\/h2>\n

Dr Paloma H Giangrande officially assumed her role as Chief Technology Officer at Eleven Therapeutics<\/a> on January 2nd, 2024.<\/p>\n<\/p><\/div>\n